2023
DOI: 10.1097/md.0000000000034731
|View full text |Cite
|
Sign up to set email alerts
|

The study of different dosages of remazolam combined with sufentanil and propofol on painless gastroscopy: A randomized controlled trial

Xiaohong Wu,
Lin Zeng,
Tianyao Zhang
et al.

Abstract: Background: Gastroscopy is one of the most commonly used diagnostic modalities for upper gastrointestinal disorders. Remazolam besylate, a new type of ultrashort-acting benzodiazepine drug, has been less studied in gastroscopy. In this study, we studied the efficacy and safety of remazolam combined with propofol for painless gastroscopy. Methods: This is a single-center, randomized controlled clinical trial. Hundred patients undergoing painless gastrosc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 34 publications
0
1
0
Order By: Relevance
“…remimazolam is a promising anesthetic agent for clinical application 23 . Wu et al 24 found that remimazolam produces a low rate of circulatory inhibition and it is e cacy and safe in painless gastroscopy, painless colonoscopy, beroptic bronchoscopy and abortion surgery. Remimazolam likely increases the tolerance to the endotracheal tube by its sedative effect ,thus reduce the throat response to extubation,similar to dexmedetomidine.…”
Section: Discussionmentioning
confidence: 99%
“…remimazolam is a promising anesthetic agent for clinical application 23 . Wu et al 24 found that remimazolam produces a low rate of circulatory inhibition and it is e cacy and safe in painless gastroscopy, painless colonoscopy, beroptic bronchoscopy and abortion surgery. Remimazolam likely increases the tolerance to the endotracheal tube by its sedative effect ,thus reduce the throat response to extubation,similar to dexmedetomidine.…”
Section: Discussionmentioning
confidence: 99%